The role of levetiracetam in treatment of seizures in brain tumor patients

Ekokobe Fonkem, Paul Bricker, Diana Mungall, Jose Aceves, Eromata Ebwe, Wei Tang, Batool Kirmani

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Levetiracetam, trade name Keppra, is a new second generation antiepileptic drug that is being increasingly used in brain tumor patients. In patients suffering with brain tumors, seizures are one of the leading neurologic complications being seen in more than 30% of patients. Unlike other antiepileptic drugs, levetiracetam is proposed to bind to a synaptic vesicle protein inhibiting calcium release. Brain tumor patients are frequently on chemotherapy or other drugs that induce cytochrome P450, causing significant drug interactions. However, levetiracetam does not induce the P450 system and does not exhibit any relevant drug interactions. Intravenous delivery is as bioavailable as the oral medication allowing it to be used in emergency situations. Levetiracetam is an attractive option for brain tumor patients suffering from seizures, but also can be used prophylactically in patients with brain tumors, or patients undergoing neurological surgery. Emerging studies have also demonstrated that levetiracetam can increase the sensitivity of Glioblastoma tumors to the chemotherapy drug temozolomide. Levetiracetam is a safe alternative to conventional antiepileptic drugs and an emerging tool for brain tumor patients combating seizures.

Original languageEnglish (US)
Article numberArticle 153
JournalFrontiers in Neurology
Volume4 OCT
DOIs
StatePublished - Oct 16 2013
Externally publishedYes

Fingerprint

etiracetam
Brain Neoplasms
Seizures
Anticonvulsants
temozolomide
Therapeutics
Drug Interactions
Drug Therapy
Synaptic Vesicles
Glioblastoma

Keywords

  • Antiepileptic drugs
  • Brain tumor patients
  • Intravenous levetiracetam
  • Neurologic complications
  • Seizures

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Fonkem, E., Bricker, P., Mungall, D., Aceves, J., Ebwe, E., Tang, W., & Kirmani, B. (2013). The role of levetiracetam in treatment of seizures in brain tumor patients. Frontiers in Neurology, 4 OCT, [Article 153]. https://doi.org/10.3389/fneur.2013.00153

The role of levetiracetam in treatment of seizures in brain tumor patients. / Fonkem, Ekokobe; Bricker, Paul; Mungall, Diana; Aceves, Jose; Ebwe, Eromata; Tang, Wei; Kirmani, Batool.

In: Frontiers in Neurology, Vol. 4 OCT, Article 153, 16.10.2013.

Research output: Contribution to journalReview article

Fonkem, E, Bricker, P, Mungall, D, Aceves, J, Ebwe, E, Tang, W & Kirmani, B 2013, 'The role of levetiracetam in treatment of seizures in brain tumor patients', Frontiers in Neurology, vol. 4 OCT, Article 153. https://doi.org/10.3389/fneur.2013.00153
Fonkem, Ekokobe ; Bricker, Paul ; Mungall, Diana ; Aceves, Jose ; Ebwe, Eromata ; Tang, Wei ; Kirmani, Batool. / The role of levetiracetam in treatment of seizures in brain tumor patients. In: Frontiers in Neurology. 2013 ; Vol. 4 OCT.
@article{21d2559e3fca470e873ef03b814ecfd3,
title = "The role of levetiracetam in treatment of seizures in brain tumor patients",
abstract = "Levetiracetam, trade name Keppra, is a new second generation antiepileptic drug that is being increasingly used in brain tumor patients. In patients suffering with brain tumors, seizures are one of the leading neurologic complications being seen in more than 30{\%} of patients. Unlike other antiepileptic drugs, levetiracetam is proposed to bind to a synaptic vesicle protein inhibiting calcium release. Brain tumor patients are frequently on chemotherapy or other drugs that induce cytochrome P450, causing significant drug interactions. However, levetiracetam does not induce the P450 system and does not exhibit any relevant drug interactions. Intravenous delivery is as bioavailable as the oral medication allowing it to be used in emergency situations. Levetiracetam is an attractive option for brain tumor patients suffering from seizures, but also can be used prophylactically in patients with brain tumors, or patients undergoing neurological surgery. Emerging studies have also demonstrated that levetiracetam can increase the sensitivity of Glioblastoma tumors to the chemotherapy drug temozolomide. Levetiracetam is a safe alternative to conventional antiepileptic drugs and an emerging tool for brain tumor patients combating seizures.",
keywords = "Antiepileptic drugs, Brain tumor patients, Intravenous levetiracetam, Neurologic complications, Seizures",
author = "Ekokobe Fonkem and Paul Bricker and Diana Mungall and Jose Aceves and Eromata Ebwe and Wei Tang and Batool Kirmani",
year = "2013",
month = "10",
day = "16",
doi = "10.3389/fneur.2013.00153",
language = "English (US)",
volume = "4 OCT",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - The role of levetiracetam in treatment of seizures in brain tumor patients

AU - Fonkem, Ekokobe

AU - Bricker, Paul

AU - Mungall, Diana

AU - Aceves, Jose

AU - Ebwe, Eromata

AU - Tang, Wei

AU - Kirmani, Batool

PY - 2013/10/16

Y1 - 2013/10/16

N2 - Levetiracetam, trade name Keppra, is a new second generation antiepileptic drug that is being increasingly used in brain tumor patients. In patients suffering with brain tumors, seizures are one of the leading neurologic complications being seen in more than 30% of patients. Unlike other antiepileptic drugs, levetiracetam is proposed to bind to a synaptic vesicle protein inhibiting calcium release. Brain tumor patients are frequently on chemotherapy or other drugs that induce cytochrome P450, causing significant drug interactions. However, levetiracetam does not induce the P450 system and does not exhibit any relevant drug interactions. Intravenous delivery is as bioavailable as the oral medication allowing it to be used in emergency situations. Levetiracetam is an attractive option for brain tumor patients suffering from seizures, but also can be used prophylactically in patients with brain tumors, or patients undergoing neurological surgery. Emerging studies have also demonstrated that levetiracetam can increase the sensitivity of Glioblastoma tumors to the chemotherapy drug temozolomide. Levetiracetam is a safe alternative to conventional antiepileptic drugs and an emerging tool for brain tumor patients combating seizures.

AB - Levetiracetam, trade name Keppra, is a new second generation antiepileptic drug that is being increasingly used in brain tumor patients. In patients suffering with brain tumors, seizures are one of the leading neurologic complications being seen in more than 30% of patients. Unlike other antiepileptic drugs, levetiracetam is proposed to bind to a synaptic vesicle protein inhibiting calcium release. Brain tumor patients are frequently on chemotherapy or other drugs that induce cytochrome P450, causing significant drug interactions. However, levetiracetam does not induce the P450 system and does not exhibit any relevant drug interactions. Intravenous delivery is as bioavailable as the oral medication allowing it to be used in emergency situations. Levetiracetam is an attractive option for brain tumor patients suffering from seizures, but also can be used prophylactically in patients with brain tumors, or patients undergoing neurological surgery. Emerging studies have also demonstrated that levetiracetam can increase the sensitivity of Glioblastoma tumors to the chemotherapy drug temozolomide. Levetiracetam is a safe alternative to conventional antiepileptic drugs and an emerging tool for brain tumor patients combating seizures.

KW - Antiepileptic drugs

KW - Brain tumor patients

KW - Intravenous levetiracetam

KW - Neurologic complications

KW - Seizures

UR - http://www.scopus.com/inward/record.url?scp=84885338717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885338717&partnerID=8YFLogxK

U2 - 10.3389/fneur.2013.00153

DO - 10.3389/fneur.2013.00153

M3 - Review article

C2 - 24109474

AN - SCOPUS:84885338717

VL - 4 OCT

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

M1 - Article 153

ER -